1. In Vivo
  2. >>Deal-Making

Podcast: Improving Communication – The Relationship Between Biotech And Pharma

 
• By David Wild

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

In Vivo Podcast
• Source: Shutterstock

"My policy as a doctor was always to be very open and transparent – whether that was about morbidity or mortality I was very open.” 

In this latest instalment of the In Vivo podcast, Treehill Partners founder, CEO and chair Ali Pashazadeh focuses on the need for increased communication between biotech and pharma and their contract organizations (both research and development/manufacturing organizations). Pashazadeh also analyzes how his previous medical experience guides him now, as he attempts to transfer the same ethos held as a doctor and clinician to the world of investment banking.

Timestamps:

  • Introduction - 00:00
  • Clinal development optimization model - 2:37
  • Transferring between industries – 7:06
  • To what extent will AI impact research? - 11:56
  • China and the importance of early data - 15:23
  • Looking ahead - 16:35  

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.